Teriparatide in the management of osteoporosis

References

• AgrawalSKruegerDCEngelkeJA2006Between-meal risedronate does not alter bone turnover in nursing home residentsJ Am Geriatr Soc54790516696745
   PubMed Web of Science ®Google Scholar
• Barrett-ConnorESirisESWehrenLE2005Osteoporosis and fracture risk in women of different ethnic groupsJ Bone Miner Res201859415647811
   PubMed Web of Science ®Google Scholar
• BlackDMBilezikianJPEnsrudKE2005One year of alendronate after one year of parathyroid hormone (1–84) for osteoporosisN Engl J Med3535556516093464
   PubMed Web of Science ®Google Scholar
• BlackDMGreenspanSLEnsrudKE2003The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosisN Engl J Med34912071514500804
   PubMed Web of Science ®Google Scholar
• BlackDMSchwartzAVEnsrudKE2006Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trialJAMA29629273817190893
   PubMed Web of Science ®Google Scholar
• BodyJJGaichGAScheeleWH2002A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1–34)] with alendronate in postmenopausal women with osteoporosis. [see comment]J Clin Endocrinol Metab8745283512364430
   PubMed Web of Science ®Google Scholar
• BoonenSMarinFMellstromD2006Safety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspectiveJ Am Geriatr Soc54782916696744
   PubMed Web of Science ®Google Scholar
• BurgeRDawson-HughesBSolomonDH2007Incidence and economic burden of osteoporosis-related fractures in the United States, 2005–2025J Bone Miner Res224657517144789
   PubMed Web of Science ®Google Scholar
• CauleyJAThompsonDEEnsrudKC2000Risk of mortality following clinical fracturesOsteoporos Int115566111069188
   PubMed Web of Science ®Google Scholar
• CenterJRNguyenTVSchneiderD1999Mortality after all major types of osteoporotic fracture in men and women: an observational studyLancet3538788210093980
   PubMed Web of Science ®Google Scholar
• CooperCAtkinsonEJJacobsenSJ1993Population-based study of survival after osteoporotic fracturesAm J Epidemiol137100158317445
   PubMed Web of Science ®Google Scholar
• CooperCAtkinsonEJO’FallonWM1992Incidence of clinically diagnosed vertebral fractures: a population-based study in Rochester, Minnesota, 1985–1989J Bone Miner Res722171570766
   PubMed Web of Science ®Google Scholar
• CosmanFNievesJWoelfertL2001Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawalJ Bone Miner Res1659253111341338
   PubMed Web of Science ®Google Scholar
• CosmanFNievesJZionM2005Daily and cyclic parathyroid hormone in women receiving alendronateN Engl J Med35365667516093465
   PubMed Web of Science ®Google Scholar
• CramerJALynchNOGaudinAF2006The effect of dosing frequency on compliance and persistence with bisphosphonate therapy in postmenopausal women: a comparison of studies in the United States, the United Kingdom, and FranceClin Ther281016869417157124
   PubMed Web of Science ®Google Scholar
• Dargent-MolinaPFavierFGrandjeanH1996Fall-related factors and risk of hip fracture: the EPIDOS prospective studyLancet348902114598684153
   PubMed Web of Science ®Google Scholar
• DelmasPDMarinFMarcusR2007Beyond hip: importance of other nonspinal fracturesAm J Med1205381717466644
   PubMed Web of Science ®Google Scholar
• DelmasPDSeemanE2004Changes in bone mineral density explain little of the reduction in vertebral or nonvertebral fracture risk with antiresorptive therapyBone34459960415050889
   PubMed Web of Science ®Google Scholar
• DobnigHSiposAJiangY2005Early changes in biochemical markers of bone formation correlate with improvements in bone structure during teriparatide therapyJ Clin Endocrinol Metab903970715840739
   PubMed Web of Science ®Google Scholar
• DobnigHTurnerRT1997The effects of programmed administration of human parathyroid hormone fragment (1–34) on bone histomorphometry and serum chemistry in ratsEndocrinology1384607129348185
   PubMed Web of Science ®Google Scholar
• EastellRDevogelaerJPPeelNF2000Prevention of bone loss with risedronate in glucocorticoid-treated rheumatoid arthritis patientsOsteoporos Int11331710928223
   PubMed Web of Science ®Google Scholar
• EttingerBSan MartinJCransG2004Differential effects of teriparatide on BMD after treatment with raloxifene or alendronateJ Bone Miner Res197455115068497
   PubMed Web of Science ®Google Scholar
• FelsenbergDSilmanAJLuntM2002The European Prospective Osteoporosis Study Group. Incidence of vertebral fracture in Europe: results from the European Prospective Osteoporosis Study (EPOS)J Bone Miner Res177162411918229
   PubMed Web of Science ®Google Scholar
• FinkelsteinJSHayesAHunzelmanJL2003The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. [see comment]N Engl J Med34912162614500805
   PubMed Web of Science ®Google Scholar
• HaginoHOkanoTAkhterMP2001Effect of parathyroid hormone on cortical bone response to in vivo external loading of the rat tibiaJ Bone Miner Metab192445011448017
   PubMed Web of Science ®Google Scholar
• HodsmanABBauerDCDempsterDW2005Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its useEndocr Rev2668870315769903
   PubMed Web of Science ®Google Scholar
• HolickMFSirisESBinkleyN2005Prevalence of Vitamin D inadequacy among postmenopausal North American women receiving osteoporosis therapyJ Clin Endocrinol Metab9032152415797954
   PubMed Web of Science ®Google Scholar
• IOF2007Facts and statistics about osteoporosis and its impactInternational Osteoporosis Foundation
   Google Scholar
• IshijimaMYamanakaMSakamotoY2005Vitamin D insufficiency impairs the effect of alendronate for the treatment of osteoporosis in postmenopausal womenJ Bone Miner Res20Suppl 1S296
   Google Scholar
• JiangYZhaoJJMitlakBH2003Recombinant human parathyroid hormone (1–34) [teriparatide] improves both cortical and cancellous bone structureJ Bone Miner Res1819324114606504
   PubMed Web of Science ®Google Scholar
• KanisJAJohnellODe LaetC2004A meta-analysis of previous fracture and subsequent fracture riskBone353758215268886
   PubMed Web of Science ®Google Scholar
• KlotzbuecherCMRossPDLandsmanPB2000Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesisJ Bone Miner Res157213910780864
   PubMed Web of Science ®Google Scholar
• KurlandESHellerSLDiamondB2004The importance of bisphosphonate therapy in maintaining bone mass in men after therapy with teriparatide [human parathyroid hormone (1–34)]Osteoporos Int15992715175844
   PubMed Web of Science ®Google Scholar
• LaneNESanchezSModinGW1998Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trialJ Clin Investig1021627339788977
   PubMed Web of Science ®Google Scholar
• LaneNESanchezSModinGW2000Bone mass continues to increase at the hip after parathyroid hormone treatment is discontinued in glucocorticoid-induced osteoporosis: results of a randomized controlled clinical trialJ Bone Miner Res159445110804025
   PubMed Web of Science ®Google Scholar
• LeuCTLuegmayrEFreedmanLP2006Relative binding affinities of bisphosphonates for human bone and relationship to antiresorptive efficacyBone386283616185944
   PubMed Web of Science ®Google Scholar
• LindsayRNievesJFormicaC1997Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosisLancet35055059284777
   PubMed Web of Science ®Google Scholar
• MosekildeL2005Vitamin D and the elderlyClin Endocrinol (Oxf)622658115730407
   PubMed Web of Science ®Google Scholar
• NancollasGHTangRPhippsRJ2006Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatiteBone386172716046206
   PubMed Web of Science ®Google Scholar
• [NICE] National Institute for Clinical Excellence FA2004The clinical effectiveness and cost effectiveness of technologies for the secondary prevention of osteoporotic fractures in postmenopausal women [online] URL: www.nice.org.uk
   Google Scholar
• NeerRMArnaudCDZanchettaJR2001Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. [see comment]N Engl J Med34414344111346808
   PubMed Web of Science ®Google Scholar
• NOF 2007 Fast Facts on OsteoporosisNational Osteoporosis Foundation
   Google Scholar
• OrwollESScheeleWHPaulS2003The effect of teriparatide [human parathyroid hormone (1–34)] therapy on bone density in men with osteoporosisJ Bone Miner Res1891712510800
   PubMed Web of Science ®Google Scholar
• RehmanQLangTFArnaudCD2003Daily treatment with parathyroid hormone is associated with an increase in vertebral cross-sectional area in postmenopausal women with glucocorticoid-induced osteoporosisOsteoporos Int14778112577188
   PubMed Web of Science ®Google Scholar
• SaagKGEmkeyRSchnitzerTJ1998Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study GroupN Engl J Med33929299682041
   PubMed Web of Science ®Google Scholar
• SirisESBrennemanSKBarrett-ConnorE2006The effect of age and bone mineral density on the absolute, excess, and relative risk of fracture in postmenopausal women aged 50–99: results from the National Osteoporosis Risk Assessment (NORA)Osteoporos Int175657416392027
   PubMed Web of Science ®Google Scholar
• TroenBR2006Osteoporosis in older people:a tale of two studies (and three treatments)J Am Geriatr Soc54853516696755
   PubMed Web of Science ®Google Scholar
• VahleJLSatoMLongGG2002Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1–34) for 2 years and relevance to human safetyToxicol Pathol303122112051548
   PubMed Web of Science ®Google Scholar
• van StaaTPDennisonEMLeufkensHG2001Epidemiology of fractures in England and WalesBone295172211728921
   PubMed Web of Science ®Google Scholar
• van StaaTPLeufkensHGCooperC2002The epidemiology of corticosteroid-induced osteoporosis: a meta-analysisOsteoporos Int137778712378366
   PubMed Web of Science ®Google Scholar
• [WHO] World Health Organization1994Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study GroupWorld Health Organ Tech Rep Ser84311297941614
   PubMed Web of Science ®Google Scholar